Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGASUS trial of GnRH antagonist versus GnRH agonist with radiotherapy in very high-risk or locally advanced prostate cancer
2015-005098-19Phase 3Active
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of degarelix, goserelin, leuprolide and triptorelin in prostate cancer (PCa) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: progression-free survival. Started Jan 2017; status: active.
02
Drugs
degarelixgoserelinleuprolidetriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2015-005098-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005098-19.